Work

Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Year: 2016

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v128.22.3243.3243

Authors: Matthew S. Davids, Haesook T. Kim, Danielle M. Brander, Jad Bsat, Alexandra Savell, Karen Francoeur, Jeffrey Hellman, Caron A. Jacobson, Ephraim Hochberg, Ronald Takvorian, Jeremy S. Abramson, David C. Fisher, Jennifer R. Brown

Institutions: Dana-Farber Cancer Institute, Duke Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, Massachusetts General Hospital

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2586568461

FWCI: 3.058

Cites:

Cited by: 17

Related to: 10